Moderna and Merck’s mRNA Melanoma Vaccine Looks Like a Game Changer

The future of cancer treatment is looking brighter thanks to trial results jointly announced this week by the pharmaceutical companies Moderna and Merck.

On Wednesday, the companies disclosed the primary findings of a Phase 3 trial that tested their mRNA-based vaccine, which is designed to prevent people’s melanoma from returning. People who received the vaccine in combination with immunotherapy lived significantly longer without cancer reoccurrence than those who only received immunotherapy, the trial reportedly showed. If approved, this vaccine could herald an important new approach to keeping cancers at bay.

“These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality,” said Stéphane Bancel, CEO of Moderna, in a statement released by the companies.

The companies’ experimental vaccine is named intismeran autogene (previously dubbed V940 or mRNA-4157). It’s one of many next-generation cancer vaccines currently in development .

While vaccines are generally preventative —helping the body recognize threats like viruses before they arrive— cancer vaccines are typically therapeutic, used to help treat people’s existing cancer or prevent a recurrence. These vaccines, like intismeran, are often personalized to someone’s specific cancer. According to the companies, intismeran is “designed and produced using a patient’s tumor sample to identify the unique mutational signature” of their cancer. The vaccine is intended to train the body’s immune system to recognize up to 34 different neoantigens, the distinct proteins that cancer cells produce as they mutate.

This latest trial involved 1,137 patients with high-risk melanomas (stages 2B to 4), meaning their cancers were likely to return even with treatment. The patients first underwent surgery to completely remove all visible signs of the melanoma, then were randomized into two groups: People who were given Merck’s immunotherapy drug Keytruda (pembrolizumab) and people who were given Keytruda plus up to nine doses of intismeran, repeated every three weeks. Keytruda is an antibody-based drug that makes it easier for the immune system to recognize certain cancers, and it has become a standard treatment for advanced melanoma.

According to the companies, intismeran met the primary goals of the trial. People given the combination regimen had longer recurrence-free survival on average than people only on Keytruda, the companies stated. The combination group also reportedly lived longer without seeing their cancers spread, or metastasize, to other distant parts of the body.

The safety profile of the combination treatment also appeared to be in line with earlier trial results, with no new safety signals seen in the trial, the companies added. Keytruda is known to commonly cause side effects like fatigue and muscle pain, and it can potentially cause severe complications like liver or lung inflammation.